

The LAM Foundation

2002

ANNUAL
REPORT

LYMPHANGIOLEIOMYOMATOSIS

Our Mission

The LAM Foundation provides support, education, and hope to women with Lymphangioleiomyomatosis (LAM), a progressive, debilitating lung disease. Our goals are to organize, marshal the forces of the scientific community, raise LAM from obscurity, and conquer it in a decade.



The LAM Foundation

10105 Beacon Hills Drive

Cincinnati, OH 45241

Phone: (513) 777-6889 Fax: (513) 777-4109

Email: lam@one.net Website: <http://lam.uc.edu>



THE LAM FOUNDATION

2002 ANNUAL REPORT

January 1, 2002 through December 31, 2002

A Message from the Leadership



In 2002, LAM came out of the darkness and into the light. Building on the genetic discoveries of LAM Foundation scientist Dr. Henske, Dr. Krymskaya discovered that a drug called rapamycin can inhibit the growth of LAM cells. Patients with tuberous sclerosis and LAM are currently being enrolled in a rapamycin treatment trial in Cincinnati, and we expect preliminary results before the end of the year. It's breathtaking when you think about it - virtually nothing known in 1998, to a promising treatment trial in 2003. Our progress is the product of defiance and passion; from the patients and families who refuse to accept a death sentence, to the scientists who lay awake thinking of new experiments and treatments.

To those who have collaborated and shared our vision, please accept our heartfelt gratitude. Your donations make research projects possible, and your partnership is as much of a key to the cure as that of our scientists. The seed money that you have provided funded four additional research projects this year, and our research was strengthened through an additional \$2 million acquired by two of our scientists from the National Institutes of Health. Another landmark accomplishment of 2002 was the formation of a consensus panel of LAM experts charged with examining critical clinical questions in LAM, with the broad objective of improving the quality of life for women with LAM.

Our annual conference was again hailed as a model for scientific exchange and personal motivation. The inspiration flowed in all directions, from scientist to scientist, patient to patient, and especially from patient to scientist. The transformation that occurs is a wonder to behold. The pace of progress in LAM attests to the humanity and goodness of the LAM scientific community, and the passion that the patient/investigator interactions have inspired.

For 2003, we pledge impatience and wise investment of the resources you provide us. We must find the means to support a broadening research program which includes critical basic research as well as expensive clinical trials. Our goal is to conquer this disease in a decade. Be assured that we are on the right track.

Sue Byrnes, Director

Aaron Dichter, Board Chairman

Frank McCormack, Scientific Director

The LAM Foundation 2002 Scientific Awards



Donna Davies, BSc, PhD, works in the Respiratory Cell and Molecular Biology Division of the University of Southampton. Her \$10,000 pilot project award will launch new studies examining the involvement of the epidermal growth factor receptor (EGFR/ErbB1) and its ligands in the abnormal growth of LAM cells.




The lab of **David Kwiatkowski, MD, PhD**, Harvard Medical School, Brigham & Women's Hospital, has been awarded a \$32,223 two-year special project award to study the effects of CCI-779, an analogue of rapamycin, on AML/LAM-like liver hemangiomas. TSC1 and TSC2 heterozygous mice develop liver hemangiomas that are similar to both LAM and kidney AML.



Xiaoning Zhe, MD, PhD, is a research associate in Dr. Lucia Schuger's lab at Wayne State University School of Medicine. His \$120,000 three-year fellowship award will allow him to explore strategies to correct the proteolytic imbalance that causes lung destruction in LAM.

Our Central Mission - Research



Total committed monies to research



Frank McCormack, MD, John Bissler, MD, and David Franz, MD, of the University of Cincinnati were awarded a \$100,000 grant to perform a phase I/II trial of rapamycin for the treatment of angiomyolipomas in patients with tuberous sclerosis and sporadic LAM. Approximately thirty patients will be enrolled, treated with escalating doses of rapamycin, and monitored for changes in tumor volume, lung function and other central nervous system lesions.


STATEMENT OF ACTIVITIES

	2002			2001
	<i>Unrestricted</i>	<i>Temporarily Restricted</i>	<i>Total</i>	<i>Total</i>
REVENUES, SUPPORT & GAINS				
Support	\$726,284	\$8,440	\$734,724	\$752,050
Dividends, Interest & Gains	(7,373)		(7,373)	25,112
Total Revenues, Support and Gains	718,911	8,440	727,351	777,162
EXPENSES				
Program Services	590,019		590,019	767,883
Management and General	47,935		47,935	39,261
Fundraising	55,859		55,859	21,701
Total Expenses	693,813		693,813	828,845
Increase (Decrease) in Net Assets	\$25,098	\$8,440	\$33,538	(\$51,683)


STATEMENT OF FINANCIAL POSITION

	2002	2001
ASSETS		
Current Assets		
Cash	\$403,710	\$380,802
Accounts receivable	47,210	39,000
Other assets	7,530	533
Investments	122,597	120,004
Total Current Assets	581,047	540,339
Property and equipment, net	14,115	12,985
Total Assets	\$595,162	\$553,324
LIABILITIES - NET ASSETS		
Current Liabilities		
Accounts payable	\$14,084	\$1,150
Compensation payable	6,403	5,334
Payroll taxes payable	3,843	7,260
Fellowships payable	317,822	320,108
Total Current Liabilities	342,152	333,852
Net Assets		
Unrestricted	236,570	211,472
Temporarily restricted	16,440	8,000
Total Net Assets	253,010	219,472
Total Liabilities and Net Assets	\$595,162	\$553,324

SUPPORT



EXPENSES



Copies of The LAM Foundation's complete 2002 audited financial statements are available upon request.

THE L·A·M FOUNDATION



10105 BEACON HILLS DRIVE
CINCINNATI, OH 45241-1335

Tel: 513-777-6889

Fax: 513-777-4109

Email: lam@one.net

Website: <http://lam.uc.edu>

ANNUAL REPORT 2002

Non-Profit
Organization
U.S. POSTAGE

PAID
CINCINNATI, OH
PERMIT NO. 1481

The LAM Foundation

EXECUTIVE COMMITTEE

Sue Byrnes, President

Cincinnati, OH

Sam Reynolds, Vice President

Mason, OH

Valerie Babb, Secretary

Minot, ND

Aaron Dichter, Chairman

Bellevue, WA

Richard Aquilina, PhD

Vice Chairman

Poquott, NY

Francis McCormack, MD

Scientific Director

Terrace Park, OH

BOARD OF TRUSTEES

Francis Byrnes

Cincinnati, OH

Jeffrey Caden

Seattle, WA

Barry Crown

Chicago, IL

Richard Denoyer

Cincinnati, OH

Austine Heldman

Cincinnati, OH

Brent Jaquet

Edgewater, MD

Brian Kleps

Bridgeport, CT

Gianni Migliorini

Occoquan, VA

Susan Milligan

Cincinnati, OH

Madeline Nolan

Naugatuck, CT

Ed Plocharczyk

Zionsville, IN

Pat Rubadeau, PhD

Ann Arbor, MI

Joshua Teeter

North Providence, RI

Thomas Toner

Huntington, CT

Charles Wehland

Wilmette, IL

SCIENTIFIC DIRECTOR

Francis McCormack, MD

University of Cincinnati Medical Center, OH

BASIC SCIENCE ADVISORY BOARD

Thomas Colby, MD

Mayo Clinic Scottsdale, AZ

Jilly Evans, PhD

Merck & Company, PA

Barry Fanburg, MD

New England Medical Center, MA

Elizabeth Henske, MD

Fox Chase Cancer Center, PA

Deborah Hunter, PhD

Incyte Genomics, Inc., DE

Sharon Long, PhD

Stanford University, CA

Joel Moss, MD, PhD

National Institutes of Health (NIH), MD

Reynold Panettieri, MD

University of Pennsylvania Medical Center, PA

Alan B. Sachs, MD, PhD

Rosetta Inpharmatics LLC, WA

Jeffrey Whitsett, MD

Children's Hospital Medical Center, OH

Ray Yeung, MD

Washington School of Medicine, WA

HONORARY BOARD MEMBERS

The Honorable Michael Bilirakis, MC

The Honorable Steve Chabot

The Honorable John Glenn

The Honorable Barbara Mikulski

The Honorable John Porter

CLINICAL ADVISORY BOARD

John Bissler, MD

Children's Hospital Medical Center, OH

Thomas Corbridge, MD

Northwestern University Medical School, IL

Jean-Francois Cordier, MD

Hospital Louis Pradel, France

David Franz, MD

Children's Hospital Medical Center, OH

Janet Maurer, MD

CIGNA HealthCare, CT

Sonoko Nagai, MD

Kyoto University Graduate School, Japan

Thomas Raffin, MD

Stanford University Medical Center, CA

Jay Ryu, MD

Mayo Clinic, MN

Steven Sahn, MD

Medical University of South Carolina, SC

Marvin Schwarz, MD

University of Colorado Health Sciences Ctr., CO

Moises Selman, MD

Instituto Nacional de Enfermedades Respiratorias,
Mexico, D.F.

Eugene Sullivan, MD

Olney, MD

Anne Tattersfield, MD

The University of Nottingham, England

Elbert Trulock, MD

Washington University Medical Center, MO